Indica Labs

What Indica Labs does

Indica Labs, founded in 2011 and headquartered in Albuquerque, New Mexico, is a privately held software company (Indica Labs, LLC) that develops the HALO suite of AI-powered digital pathology image analysis solutions deployed in over 3,000 customer sites globally. The platform spans research and clinical use cases: HALO provides quantitative image analysis for whole-slide images across H&E, IHC, fluorescence, multiplex IHC, ISH/FISH, spatial, and tissue microarray workflows; HALO AI adds trainable deep learning for tissue classification, nuclear and membrane segmentation, and cell phenotyping with no-programming custom model training; HALO Link provides collaborative image management for distributed research teams. For clinical diagnostics, the company offers HALO AP and the FDA-cleared HALO AP Dx for primary anatomic pathology workflows, alongside CE-IVD-marked Clinical AI tools including Prostate AI, Breast IHC AI (quantifying HER2, ER, PR, Ki67), Lung PD-L1 AI, SlideQC BF, and Macrodissection solutions for lung and colorectal cancer, plus an AI-Powered Companion Diagnostics service.

The company generates revenue through recurring software licenses (subscription and perpetual enterprise site licenses for pharma, diagnostic labs, hospitals, and academia), AWS-hosted HALO Cloud Services, professional services for companion diagnostic development and clinical trial biomarker analysis, and integration/migration services, all on quote-based annual or multi-year billing. Its customer base is diversified across the top 20 global pharmaceutical companies, high-volume molecular profiling labs (Caris Life Sciences), academic medical centers (UCSF, University of Washington, Medical University of Graz), government research institutes (National Cancer Institute), and hospital pathology departments including Nottingham University Hospitals NHS Trust and IPATIMUP.

Indica Labs operates regional offices in the United Kingdom, Japan, and China with employee presence in 12 countries, and maintains a strategic distribution and co-development partnership with Leica Biosystems (Danaher) covering Aperio HALO AP and Aperio HALO AP Dx. Additional strategic partners include Lunit for PD-L1 AI algorithms, Molecular Instruments for HCR RNA-ISH, AWS for cloud hosting, and an "Open Pathology Partner" ecosystem comprising Paige, Ibex Medical Analytics, Akoya Biosciences, Hamamatsu Photonics, Biotechne/Lunaphore, Histofy.ai, Xyall, Deep Bio, and Dell Technologies. The HALO AP platform received a 94.9/100 overall customer rating in the 2026 KLAS Best in KLAS Awards for Global Software in Digital Pathology.

Name

Indica Labs

Legal name

Indica Labs, LLC

Website

https://indicalab.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

51–100 employees

Short description

Indica Labs develops AI-powered digital pathology software under the HALO brand — quantitative image analysis, FDA-cleared diagnostic workflows (HALO AP Dx), and CE-IVD AI tools — serving pharmaceutical companies, diagnostic laboratories, hospitals, and academic research institutions worldwide.

Ownership category

akta.pro rank

Product category

Digital Pathology Software

NAICS

Software Publishers (513210)

akta.pro primary industry

Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)

akta.pro secondary industries

SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG), Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)

Keywords

• Digital pathology software
• AI image analysis
• Tissue quantification
• Biomarker analysis
• Companion diagnostics

Headquarters

HQ city

Corrales

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Software Licenses: HALO platform software licenses sold on subscription or perpetual basis to pharmaceutical companies, diagnostic labs, research organizations, and hospitals for digital pathology image analysis.
2. Cloud Services: AWS-hosted HALO Cloud Services providing cloud-based deployment options for organizations preferring cloud infrastructure over on-premise installations.
3. Pharma Services: Contract services for pharmaceutical companies including companion diagnostics development and support for clinical trials using HALO platform capabilities.
4. Integration and Migration Services: Professional services for database migrations, system integrations, and implementation support for enterprise deployments.
5. Software Maintenance and Support: Ongoing technical support, software updates, and maintenance coverage (SMS) for licensed customers.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels9 records

Core offering

Indica Labs develops and licenses the HALO software suite — an AI-powered digital pathology platform used to analyze whole-slide images for quantitative tissue, biomarker, multiplex IHC, FISH/ISH, and spatial analysis. Offerings include the FDA-cleared HALO AP Dx diagnostic platform, a CE-IVD Clinical AI suite (Prostate AI, Breast IHC AI, Lung PD-L1 AI, SlideQC BF), HALO Cloud Services on AWS, and Pharma Services for companion-diagnostic development and clinical-trial biomarker analysis.

Product overview

Indica Labs provides a comprehensive AI-powered digital pathology software suite under the HALO brand, spanning research and clinical applications. The core HALO platform offers quantitative image analysis with specialized modules (HALO AI for deep learning, HALO Link for collaboration, and domain-specific modules for multiplex IHC, ISH/FISH, spatial analysis, and tissue microarrays). For clinical diagnostics, HALO AP and HALO AP Dx (FDA-cleared) provide enterprise digital pathology workflows, complemented by Clinical AI solutions including Prostate AI, Breast IHC AI, Lung PD-L1 AI, SlideQC BF, and Macrodissection tools. Cloud Services enables AWS-hosted deployment, while Pharma Services and AI-Powered Companion Diagnostics provide contract research offerings. The products are available through direct licensing, cloud deployment, and strategic partnerships including Leica Biosystems, Lunit, and Molecular Instruments.

Differentiator

Problem solved

Functional benefit

Brands

• HALO: Quantitative image analysis platform for pathology
• HALO AI
• HALO Link
• HALO AP
• HALO AP Dx
• HALO Clinical AI

Products and services

• HALO Quantitative image analysis platform for pathology providing fast, reproducible evaluation of whole-slide images for research applications across brightfield and fluorescence modalities.
• HALO AI Deep learning classifier add-on enabling trainable AI for tissue classification, nuclear/membrane segmentation, and cell phenotyping, with pretrained networks, custom model training, and ONNX model import/export.
• HALO Link Collaborative image management platform enabling remote image analysis, annotation sharing, and secure file collaboration across distributed research and clinical teams.
• HALO AP Dx FDA-cleared case-centric pathology platform enabling primary diagnosis, remote working, and routine diagnostic workflows in anatomic pathology.
• HALO AP AI-powered, pathologist-driven case-centric pathology platform for enterprise clinical workflows supporting image evaluation, collaboration, and clinical trial management.
• Prostate AI CE-IVD marked AI tool that detects and grades prostate adenocarcinoma in core needle biopsy specimens.
• Breast IHC AI Quantifies HER2, ER, PR, and Ki67 IHC expression levels in primary invasive breast cancer specimens.
• Lung PD-L1 AI Quantifies PD-L1 expression in NSCLC IHC specimens using automated tumor proportion scoring.
• SlideQC BF Detects air bubbles, tissue folds, and other common artifacts in H&E- and IHC-stained whole-slide images for automated quality control.
• HALO Macrodissection Solutions Quantifies tumor content and generates tumor density heatmaps to guide ROI selection for macrodissection, including Lung, CRC, and Breast Macrodissect AI tools.
• Cloud Services AWS-hosted cloud deployment of HALO software enabling collaborative research, reduced infrastructure costs, and easy collaboration with institutions across locations.
• Pharma Services Contract research services leveraging HALO platforms for pharmaceutical and biotech companies, including preclinical and clinical trial biomarker analysis.
• AI-Powered Companion Diagnostics (CDx) End-to-end companion-diagnostic development services including AI algorithm development, validation, and regulatory submission support for precision-medicine applications.
• HALO Module Suite (Multiplex IHC, Spatial Analysis, ISH, FISH, Highplex FL, TMA, ADC Target Scoring) Specialty HALO analysis modules for multiplex chromogenic IHC, fluorescence in situ hybridization, spatial analysis, multiplex fluorescence, tissue microarrays, and antibody-drug conjugate target scoring.
• Software Maintenance and Support (SMS) Ongoing technical support, software updates, and maintenance coverage for licensed HALO customers.
• Integration and Migration Services Professional services for database migrations, system integrations, and implementation support for enterprise HALO deployments.

Quantifiable outcome

• 94.9/100 overall customer rating in 2026 KLAS Best in KLAS Awards for digital pathology
• +3 more outcomes

Named customers10 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration6 records

AI capability5 records

Feature6 records

Partnerships

13 partnerships are on record, tiered core, flagship and secondary.

• LunitcoreStrategic or Co-development Partner · 26 May 2026Strategic alliance for seamless integrated digital pathology AI workflows. Partnership combines Lunit's SCOPE AI algorithms with Indica Labs' workflow software for standardized biomarker quantification. First product is AI-powered Lunit SCOPE algorithm for Leica Biosystems' PD-L1 primary antibody (CAL10). Focus on PD-L1 and emerging immunohistochemistry biomarkers for scalable, consistent biomarker quantification.
• Leica Biosystems (Danaher)flagshipStrategic or Co-development Partner · 1 October 2025Strategic investment and partnership for digital pathology platform development. Collaboration includes co-development of Aperio HALO AP for Leica's Aperio GT 450 DX scanner, integrated clinical digital pathology ecosystem, and joint AI-powered solutions including Aperio HALO AP Dx software launch. Partnership announced as 'groundbreaking' with goal to accelerate next-generation AI-enabled solutions in cancer diagnostics.
• Molecular InstrumentscoreTechnology or Integration · 5 April 2024Partnership to co-market compatibility between Molecular Instruments' HCR Imaging technology and Indica's HALO software. Enables AI-powered quantitative image analysis with HCR RNA-ISH assays for researchers studying gene expression in tissue context.
• AWS (Amazon Web Services)coreTechnology or IntegrationCloud hosting partner for HALO Cloud Services enabling cloud-based deployment of Indica Labs' digital pathology platform on AWS infrastructure. Supports enterprise cloud deployments for National Cancer Institute, University of Bern, and other customers.
• Hamamatsu PhotonicssecondaryTechnology or IntegrationScanner hardware partner supplying whole slide imaging scanners. Deployed at Nottingham University Hospitals NHS Trust and other customer sites as part of integrated digital pathology solutions.
• Ibex Medical AnalyticssecondaryTechnology or IntegrationPartner for AI-powered digital pathology solutions ecosystem. Listed as open pathology partner for integrated digital pathology workflows.
• PaigesecondaryTechnology or IntegrationDigital pathology AI company partner for open pathology ecosystem integration.
• Akoya BiosciencessecondaryTechnology or IntegrationMultiplex fluorescence imaging partner for spatial profiling integration. CODEX/Akoya multiplex stain analysis supported in HALO platform.
• Biotechne/LunaphoresecondaryTechnology or IntegrationTechnology partner for multiplex immunohistochemistry solutions integrated with HALO platform.
• Histofy.aisecondaryTechnology or IntegrationOpen pathology partner for AI-powered digital pathology solutions ecosystem.
• XyallsecondaryTechnology or IntegrationOpen pathology partner for digital pathology AI solutions ecosystem.
• Deep BiosecondaryTechnology or IntegrationAI pathology company partner in open pathology ecosystem for integrated digital pathology solutions.
• Dell TechnologiessecondaryTechnology or IntegrationTechnology infrastructure partner for digital pathology solutions.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Paige: Paige is an AI-powered digital pathology company with FDA-cleared prostate cancer detection algorithms and a similar enterprise pharma and clinical focus. It is the most direct competitor to Indica Labs' HALO AP Dx and Clinical AI product lines, and is also a partner in Indica's open pathology ecosystem.
• Ibex Medical Analytics: Ibex is an Israel-based AI digital pathology company focused on clinical-grade cancer detection algorithms (e.g., breast, prostate, GI) used by labs and hospitals. It directly competes with Indica Labs' Clinical AI Solutions and HALO AP Dx offering, and also appears as an Indica open pathology partner.
• PathAI: PathAI provides AI-powered pathology solutions for both research (biopharma services) and clinical diagnostics, serving many of the same top-20 pharma customers and academic centers as Indica Labs. It is a direct competitor in the AI-orchestration and biomarker quantification space.
• Lunit: Lunit is a Korea-based AI company specializing in cancer diagnostics including PD-L1 quantification, which directly overlaps with Indica's Lung PD-L1 AI and was announced in May 2026 as a strategic partner integrating with HALO AP. It remains a competitor for biomarker quantification work in pharma and clinical markets.

Broad incumbents

• Roche Digital Pathology (Ventana): Roche's Ventana business is the dominant incumbent in anatomic pathology, offering whole-slide scanners, staining platforms, and an expanding AI/image-analysis portfolio that overlaps with Indica Labs' quantitative IHC and clinical AI tools. Customers often evaluate Roche and Indica as alternative enterprise digital pathology stacks.
• Philips Digital Pathology: Philips IntelliSite Pathology Solution is a broad-incumbent enterprise digital pathology platform combining scanners, PACS, and workflow software with image analysis. It competes with HALO AP for enterprise pathology department contracts in hospitals and academic medical centers.
• Leica Biosystems (Danaher): Leica Biosystems is Indica Labs' largest strategic partner (with Danaher strategic investment) and also a broader-incumbent competitor through its Aperio scanner line and now co-developed Aperio HALO AP. The relationship is mutually strategic but creates customer overlap in enterprise pathology accounts.

Emerging players

• Aignostics: Aignostics is a Berlin-based AI pathology spin-out focused on computational pathology for pharma biomarker discovery and clinical decision support. It overlaps with Indica Labs' HALO research and pharma services offering on quantitative biomarker analysis for top pharma clients.
• Owkin: Owkin is a France-based AI-biopharma company with a growing digital pathology footprint (including its Mosaiq pathology solution) and pharma AI platform. It competes for the same biopharma research and companion diagnostic engagements that Indica Labs targets with HALO and Pharma Services.
• Deep Bio: Deep Bio is a Korea-based AI pathology company offering clinical cancer detection and quantification algorithms (prostate, breast, etc.) with regulatory clearances in multiple geographies. It is listed as an Indica open pathology partner but also competes for clinical AI pathology contracts.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@IndicaLabs
• Facebookfacebook.com/IndicaLabs.HALO
• LinkedInlinkedin.com/company/indica-labs
• Xx.com/indica_labs

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Indica Labs